Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease

Published:2019-06 Issue:3 Volume:41 Page:317-324
ISSN:0163-4356
Container-title:Therapeutic Drug Monitoring
language:en
Short-container-title:

Author:

van Hoeve Karen,Dreesen Erwin,Hoffman Ilse,Van Assche Gert,Ferrante Marc,Gils Ann,Vermeire Séverine

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

Reference50 articles.

1. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease;Ruemmele;J Crohns Colitis.,2014

2. Management of pediatric ulcerative colitis, Part 2: acute severe colitis; an evidence-based consensus guideline from ECCO and ESPGHAN;Turner;J Pediatr Gastroenterol Nutr.,2018

3. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children;Hyams;Gastroenterology.,2007

4. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis;Hyams;Clin Gastroenterol Hepatol.,2012

5. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center;Nobile;Eur J Gastroenterol Hepatol.,2014

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease;Expert Opinion on Biological Therapy;2024-07-02

2. Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease;Frontiers in Immunology;2024-02-22

3. Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel disease;Journal of Pediatric Gastroenterology and Nutrition;2024-02-09

4. Evaluation of selected serum biomarkers levels in response to the infliximab reference product (Remicade®) versus its biosimilar (Remsima®) in a sample of ulcerative colitis patients: a cross-sectional study;F1000Research;2023-12-06

5. Similar Growth Outcomes in Children with Inflammatory Bowel Disease Initiated on Infliximab Originator or Biosimilar;Journal of Pediatric Gastroenterology & Nutrition;2023-09-20